# US 2015/0105433 A1 · TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105433 A1
- Document ID: US20150105433A1
- Status: Published application
- Kind: A1
- Application number: 14/397,396
- Filed: 2013-04-25
- Published: 2015-04-16
- Earliest claimed: 2012-04-27
- Assignees: The UAB Research Foundation
- Applicants: The Uab Research Foundation
- Inventors: Sunnie R. Thompson
- Web page: https://patentgrep.com/patent/US20150105433A1

## CPC

- C07D 277/46: by carboxylic acids, or sulfur or nitrogen analogues thereof
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/415: 1,2-Diazoles
- A61K 31/426: 1,3-Thiazoles
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- C07C 219/28: having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C 235/56: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 213/52: Sulfur atoms
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q 2600/158: Expression markers
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided herein are methods for preventing or treating a viral infection in a subject, wherein the viral infection is mediated by a virus comprising one or more viral RNA molecules translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism. The methods comprise administering to a subject an agent that reduces ribosomal protein (Rps25) expression or function. Also provided are methods of inhibiting or promoting ribosomal shunting-mediated translation or non-IRES mediated translation. Also provided are methods of screening for an agent that inhibits or promotes ribosomal shunting-mediated translation or non-IRES mediated translation.

## Claims

### Claim 1

A method of treating or preventing a viral infection in a subject, the method comprising:
(a) identifying a subject with or at risk of developing a viral infection, wherein the viral infection is mediated by a virus comprising one or more viral RNAs that are translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism;
(b) administering to the subject a therapeutically effective amount of an agent that reduces ribosomal protein S25 (Rps25) expression or function in the subject in comparison to a control.

### Claim at position 2

2-10. (canceled)

### Claim 11 (depends on 1)

The method of claim 1, wherein the agent is a compound of the following formula:
or a pharmaceutically acceptable salt of prodrug thereof, wherein:
A is CR9 or N;
L is —O—CR10R11C(O)—NR6—, —NR12—NR6—, —C(O)—NR6—, —SO2—NR6—, —CH2—NR6—, —CH2—CH2—NR6—, or a substituted or unsubstituted heteroaryl;
n is 0, 1, or 2;
X is —CR13═CR14—, —N═CR15—, —CR15═N—, NR16, O, or S;
R1, R2, R3, R4, R5, R7, R8, R9, R10, R11, R13, R14, and R15 are each independently selected from hydrogen, halogen, hydroxyl, trifluoromethyl, substituted or unsubstituted thio, substituted or unsubstituted alkoxyl, substituted or unsubstituted aryloxyl, substituted or unsubstituted amino, substituted or unsubstituted C1-12 alkyl, substituted or unsubstituted C2-12 alkenyl, substituted or unsubstituted C2-12 alkynyl, substituted or unsubstituted C1-12 heteroalkyl, substituted or unsubstituted C2-12 heteroalkenyl, substituted or unsubstituted C2-12 heteroalkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and
R6, R12, and R16 are each independently selected from hydrogen, substituted or unsubstituted C1-12 alkyl, substituted or unsubstituted C2-12 alkenyl, substituted or unsubstituted C2-12 alkynyl, substituted or unsubstituted C1-12 heteroalkyl, substituted or unsubstituted C2-12 heteroalkenyl, substituted or unsubstituted C2-12 heteroalkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl, or substituted or unsubstituted carbonyl.

### Claim 12 (depends on 11)

The method of claim 11, wherein R1 and R2 are combined to form a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, or substituted or unsubstituted heterocycloalkynyl.

### Claim 13 (depends on 11)

The method of claim 11, wherein R2 and R3 are combined to form a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, or substituted or unsubstituted heterocycloalkynyl.

### Claim 14 (depends on 11)

The method of claim 11, wherein R3 and R4 are combined to form a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, or substituted or unsubstituted heterocycloalkynyl.

### Claim 15 (depends on 11)

The method of claim 11, wherein R5 and R6 are combined to form a substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkynyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted heterocycloalkenyl, or substituted or unsubstituted heterocycloalkynyl.

### Claim 16 (depends on 11)

The method of claim 11, wherein A is CH or N.

### Claim 17 (depends on 11)

The method of claim 11, wherein L is a substituted or unsubstituted pyrazole.

### Claim 18 (depends on 11)

The method of claim 11, wherein R3 is ethoxy, dimethylamino, or chloro.

### Claim 19 (depends on 11)

The method of claim 11, wherein X is S or —CH═CH—.

### Claim at position 12

-32. (canceled)

### Claim 33

A method of inhibiting ribosomal shunting-mediated translation or non-IRES mediated translation, the method comprising:
(a) providing a cell, wherein the cell comprises an RNA molecule that is translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism; and
(b) contacting the cell with an agent that reduces ribosomal protein S25 (Rps25) expression or function, reduction of Rps25 expression or function as compared to a control indicates that the agent inhibits ribosomal shunting-mediated translation or non-IRES mediated translation.

### Claim 34 (depends on 33)

The method of claim 33, further comprising determining that ribosomal shunting-mediated translation non-IRES mediated translation is inhibited by detecting a reduced level of protein expressed by an RNA translated by the ribosomal shunting mechanism or non-IRES mediated mechanism in comparison to a control.

### Claim at position 15

-42. (canceled)

### Claim 43

A method of screening for an agent that inhibits or promotes ribosomal shunting-mediated translation or non-IRES mediated translation, the method comprising:
(a) providing a system comprising a ribosomal protein S25 (Rps25) or a nucleic acid that encodes Rps25 and an RNA molecule translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism;
(b) contacting the system with the agent to be screened; and
(c) determining Rps25 expression or function, wherein a decrease in the level of Rps25 expression or function indicates the agent inhibits ribosomal shunting-mediated translation or non-IRES mediated translation, and wherein an increase in the level of Rps25 expression or function indicates the agent promotes ribosomal shunting-mediated translation or non-IRES mediated translation.

### Claim 44 (depends on 43)

The method of claim 43, wherein the system comprises a cell.

### Claim 45 (depends on 43)

The method of claim 43, wherein the system comprises an in vitro assay.

### Claim 46 (depends on 43)

The method of claim 43, wherein the agent to be tested is selected from the group consisting of a small molecule, a polypeptide, a nucleic acid molecule, a peptidomimetic, or a combination thereof.

### Claim 47

(canceled)

### Claim 48

A method of identifying cellular RNA molecules translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism, the method comprising:
(a) inhibiting Rps25 expression or function in a cell;
(b) determining a protein expression pattern in the cell; and
(c) comparing the protein expression pattern in the cell to a control, wherein a decrease in protein expression of a cellular RNA molecule as compared to a control indicates the cellular RNA molecule is translated by a ribosomal shunting mechanism or non-IRES mediated mechanism.

### Claim 49

A method of promoting ribosomal shunting-mediated translation or non-IRES mediated translation, the method comprising:
(a) providing a cell, wherein the cell comprises an RNA molecule translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism; and
(b) contacting the cell with an agent that increases ribosomal protein S25 (Rps25) expression or function, wherein an increase in Rps25 expression or function as compared to a control indicates that the agent promotes ribosomal shunting-mediated translation or non-IRES mediated translation.

### Claim 50 (depends on 49)

The method of claim 49, further comprising determining that ribosomal shunting-mediated translation or non-IRES mediated translation is promoted by detecting an increased level of protein encoded by the RNA molecule translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism in comparison to a control.

### Claim 51

A method of promoting ribosomal shunting-mediated translation or non-IRES mediated translation, the method comprising providing a cell with a nucleic acid encoding a Rps25 protein or functional fragment thereof.
